Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.

Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.

Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release powder formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.

Abstract: Disclosed herein are processes for formulating a protein or a peptide for oral delivery, the process comprising the steps of: obtaining a powder containing the protein or peptide; obtaining an amount of an enteric polymer, wherein the enteric polymer is neutralized so that it is soluble in water; optionally obtaining at least one excipient; mixing the protein or peptide, the neutralized enteric polymer, and optionally the at least one excipient to obtain a First Dispersion; granulating the First Dispersion on a fluidized bed to obtain a Second Dispersion; whereby the protein or peptide in the Second Dispersion undergoes less than 50% proteolysis under gastric conditions.

Abstract: Disclosed herein are processes for formulating a protein or a peptide for oral delivery, the process comprising the steps of: obtaining a powder containing the protein or peptide; obtaining an amount of an enteric polymer, wherein the enteric polymer is neutralized so that it is soluble in water; optionally obtaining at least one excipient; mixing the protein or peptide, the neutralized enteric polymer, and optionally the at least one excipient to obtain a First Dispersion; granulating the First Dispersion on a fluidized bed to obtain a Second Dispersion; whereby the protein or peptide in the Second Dispersion undergoes less than 50% proteolysis under gastric conditions.

Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.

Abstract: The present invention generally concerns an epinephrine formulation that has enhanced stability. In particular embodiments, the formulation is an injectable formulation. In specific aspects, the formulation comprises epinephrine, EDTA, and one or more of an antioxidant such as cysteine, citric acid, acetylcysteine, or thioglycerol. The formulations are suitable for any medical condition that is in need of epinephrine, although in specific embodiments the medical condition is anaphylaxis, asthma, or cardiac arrest.

Abstract: The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.

Abstract: Compositions of matter comprising sertraline and a solubilizing agent which increases the solubility of sertraline in aqueous chloride ion-containing use environments.

Abstract: Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1 mgA/hr.

Abstract: There is disclosed a two-stage enzymatically catalyzed reaction for the selective preparation of the (R)-endo-isomer of norbornenol from a mixture containing all four stereo- and regioisomers of norbornenol, as well as the synthesis of the intermediate product comprising the enantiomerically enriched mono-ester of (R)-endo-norbornenol and a diacid, and of the enantiomerically enriched saturated alcohol (R)-endo-norborneol. There is also disclosed a method for the production of (R)-endo-norborne-2-ol, by chemical reduction of either the enantiomerically enriched monoester and subsequent hydrolysis, or by hydrolysis of the enantiomerically enriched monoester and then chemical reduction.